Detalhe da pesquisa
1.
Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.
Proc Natl Acad Sci U S A
; 105(30): 10531-6, 2008 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-18647836
2.
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
J Virol
; 83(8): 3617-25, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19193787
3.
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.
J Virol
; 82(24): 12449-63, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18842730
4.
Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.
Biochemistry
; 47(25): 6662-70, 2008 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-18507398
5.
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
Antimicrob Agents Chemother
; 52(12): 4315-9, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18809940
6.
Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.
AIDS
; 18(13): 1787-94, 2004 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-15316339
7.
Initiation of human immunodeficiency virus type 1 (HIV-1) transcription is inhibited by noncytolytic CD8 suppression.
Open Virol J
; 1: 1-7, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-19440453
8.
Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.
AIDS
; 21(18): 2537-9, 2007 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-18025893
9.
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.
Proc Natl Acad Sci U S A
; 104(31): 12772-7, 2007 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-17640899
10.
HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.
J Infect Dis
; 194(2): 238-46, 2006 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16779731
11.
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
J Infect Dis
; 191(7): 1155-63, 2005 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15747252
12.
Mechanisms for HIV-1 Entry: Current Strategies to Interfere with This Step.
Curr Infect Dis Rep
; 3(1): 93-99, 2001 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11177736
13.
Resistance to enfuvirtide, the first HIV fusion inhibitor.
J Antimicrob Chemother
; 54(2): 333-40, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15231762
14.
Occupational exposure to cephalosporins leading to clostridium difficile infection.
J Toxicol Clin Toxicol
; 41(2): 205-6, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12733860